Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine in Severe Renal Impairment
NCT03904550Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Dec 2019
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Sugammadex in neuromuscular blockade (NMB), sponsored by UT Southwestern Medical Center. Primary endpoint: Time Until Complete Reversal of Neuromuscular Blockade at 30 minutes. Started Dec 2019; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03904550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904550.